Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology by ImmunityBio for Non-Small Cell Lung Cancer: Likelihood of Approval
Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer.
Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer.
What's Your Reaction?
